170 related articles for article (PubMed ID: 15580610)
21. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
22. [Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice].
Mühlau G
MMW Fortschr Med; 2004 Dec; 146(Suppl 3-4):87-93. PubMed ID: 15662897
[TBL] [Abstract][Full Text] [Related]
23. [Methadone in the treatment of chronic non-malignant pain].
Bendiksen A; McGehee E; Handberg G
Ugeskr Laeger; 2007 Apr; 169(17):1568-72. PubMed ID: 17484827
[TBL] [Abstract][Full Text] [Related]
24. [Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].
Imamura A; Tsuboi Y; Tanaka M; Obata T; Yamada T
Rinsho Shinkeigaku; 2007 Apr; 47(4):156-9. PubMed ID: 17511286
[TBL] [Abstract][Full Text] [Related]
25. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
[TBL] [Abstract][Full Text] [Related]
26. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome.
Stiasny-Kolster K; Kohnen R; Möller JC; Trenkwalder C; Oertel WH
Mov Disord; 2006 Sep; 21(9):1333-9. PubMed ID: 16705685
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
Enomoto M; Inoue Y; Namba K; Munezawa T; Matsuura M
Mov Disord; 2008 Apr; 23(6):811-6; quiz 926. PubMed ID: 18074382
[TBL] [Abstract][Full Text] [Related]
28. Regular intake of non-opioid analgesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants.
Leutgeb U; Martus P
Eur J Med Res; 2002 Aug; 7(8):368-78. PubMed ID: 12204845
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone response to low-dose apomorphine in restless legs syndrome.
Happe S; Bachmann CG; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Growth Horm IGF Res; 2007 Aug; 17(4):323-7. PubMed ID: 17512770
[TBL] [Abstract][Full Text] [Related]
30. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.
Driver-Dunckley ED; Noble BN; Hentz JG; Evidente VG; Caviness JN; Parish J; Krahn L; Adler CH
Clin Neuropharmacol; 2007; 30(5):249-55. PubMed ID: 17909302
[TBL] [Abstract][Full Text] [Related]
31. Association between restless legs syndrome and Chiari type 1 malformation.
Kaplan Y; Oksuz E
Clin Neurol Neurosurg; 2008 Apr; 110(4):408-10. PubMed ID: 18281149
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A.
Rotenberg JS; Canard K; Difazio M
J Clin Sleep Med; 2006 Jul; 2(3):275-8. PubMed ID: 17561538
[TBL] [Abstract][Full Text] [Related]
33. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
Vetrugno R; Contin M; Baruzzi A; Provini F; Plazzi G; Montagna P
Mov Disord; 2006 Feb; 21(2):254-8. PubMed ID: 16200540
[TBL] [Abstract][Full Text] [Related]
34. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study.
Walters AS; Ondo WG; Zhu W; Le W
J Neurol Sci; 2009 Apr; 279(1-2):62-5. PubMed ID: 19167016
[TBL] [Abstract][Full Text] [Related]
35. Appropriate use of dopamine agonists and levodopa in restless legs syndrome in an ambulatory care setting.
Molokwu OC
Ann Pharmacother; 2008 May; 42(5):627-32. PubMed ID: 18381842
[TBL] [Abstract][Full Text] [Related]
36. Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI).
Benes H; Kohnen R
Sleep Med; 2009 May; 10(5):515-23. PubMed ID: 18823819
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
38. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
Benes H
Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
[TBL] [Abstract][Full Text] [Related]
39. Restless legs syndrome in hemodialysis patients: association with calcium antagonists. A preliminary report.
Telarović S; Relja M; Trkulja V
Eur Neurol; 2007; 58(3):166-9. PubMed ID: 17622723
[TBL] [Abstract][Full Text] [Related]
40. Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome.
Stiasny-Kolster K; Magerl W; Oertel WH; Möller JC; Treede RD
Brain; 2004 Apr; 127(Pt 4):773-82. PubMed ID: 14985260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
